The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
The Life Raft Group Data Management & Research and Communications Team attended remotely to gain knowledge of current research in GIST and to track breaking news and social media networking. In this post, we present commentary on several presentations and posters.
ASCO’s Annual Meeting will feature GIST in 18 abstracts, posters, panels, and presentations. Here is a preview of the topics that will be presented at the conference in June.
In March, Director of Data Mgmt and Research, Sahibjeet Kaur joined the GIST experts of AIIMS for the 99th Virtual Patient Support Group addressing patients from India.
The Life Raft Group welcomes our newest Medical Advisory Board (MAB) member Dr. Neeta Somaiah of The University of Texas MD Anderson Cancer Center.
A recent paper published in Cancers by CTOS and SPAEN highlights major findings and proposes potential future steps in global sarcoma care.
Dr. Yoon-Koo Kang of the Asan Medical Center, Seoul, Korea, discusses the results of his team's study on the effect of L-carnitine in muscle cramps in GIST patients who are on imatinib.
A new article published this month is presented by the University of Texas MD Anderson Cancer Center Department of Sarcoma Medical Oncology. Understanding Sarcoma Drug Resistance One Cell at a Time discusses that the focus in GIST research is moving from the current focus on just histology, proteomics, and tumor genetics enabled by tumor samples, cell lines and mouse models which are limited in rare cancers like SDH-deficient GIST.
In this issue of LRG Science, we present additional commentary on our Sept. issue: "It's Time to Rethink Placebos in Advanced GIST".
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
